Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026 Life Science Investing
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 Life Science Investing
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers Life Science Investing
Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness Pharmaceutical Investing
Quantum-Si Announces Two Customer Posters to be Presented at the American Association of Cancer Research Annual Meeting Life Science Investing
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress Life Science Investing
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer Life Science Investing
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications Life Science Investing
neffy® Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions Life Science Investing
Innovotech Inc. Begins Trading on OTCQB Under Symbol IOTCF, Expanding Access for U.S. Investors Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
